New Uric Acid-Lowering Drug Urece Tablet Offers New Hope For Gout Patients

Japanese pharmaceutical company Fuji Yakuhin Co., Ltd. announced that Urece Tablet (Dotinurad Tablet), a novel uric acid-lowering drug developed by the company, has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is now officially available for sale.

This news brings a new treatment option to millions of gout and hyperuricemia patients worldwide.

What is The Mechanism of Action of Dotinurad?

Urece Tablet is a selective uric acid reabsorption inhibitor (SURI), whose active ingredient, Dotinurad, effectively reduces serum uric acid levels by inhibiting the uric acid transporter protein, URAT1, in the kidneys and promoting uric acid excretion.

Compared with traditional uric acid-lowering drugs (e.g., allopurinol and benzbromarone), Dotinurad Tablet has higher selectivity and fewer adverse effects, and is particularly suitable for patients who are intolerant to other drugs.

Clinical Trial Data

Urece Tablet demonstrated significant efficacy and safety in a one-year Phase III clinical trial.

The study showed that more than 80% of patients taking Dotinurad Tablet had their serum uric acid levels reduced to the target range (below 6.0 mg/dL).

In addition, the Urece Dotinurad group had a lower incidence of adverse reactions compared to the placebo group, primarily mild gastrointestinal discomfort and headache, with no serious hepatic or renal impairment reported.

Expert Evaluation

Kentaro Yamada, Professor of Rheumatology at the University of Tokyo School of Medicine, Japan, said, “The launch of Urece Tablet has brought a new breakthrough in the field of gout treatment.

Its unique mechanism of action and favorable safety profile make it an important option for patients with hyperuricemia, especially those who have not responded well to conventional treatment.”

Urece Dotinurad Patient Benefits

Gout is a chronic disease caused by elevated levels of uric acid, often accompanied by severe joint pain and inflammation.

Approximately 1% of the world’s population suffers from this disease, and its incidence is increasing every year.

The launch of Urece Tablet provides these patients with a safer and more effective treatment option that is expected to significantly improve their quality of life.

Future Outlook For Urece Tablet

Fuji Yakuhin Co., Ltd. said that in the future, it plans to expand Urece Tablet to the global market and conduct further clinical studies in different populations to explore its potential application in other related diseases, such as chronic kidney disease combined with hyperuricemia.

How To Get Urece Tablet?

Urece Tablet is currently available at major hospitals and pharmacies in Japan, and patients are required to purchase it with a doctor’s prescription. Patients are advised to consult a medical professional before using the drug to ensure safety and efficacy.

However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.

We welcome you to reach out to us to get Dotinurad price.

DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.

Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.

Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.